Allen A. Fienberg
Corporate Officer/Principal at ITI, Inc. (New York)
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sharon Mates | M | 71 |
Intra-Cellular Therapies, Inc. /Old/
 Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
| Lawrence Hineline | M | 67 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
| Michael Rawlins | M | 82 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 1 years |
| Chris D. Alafi | M | 60 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 11 years |
| Lawrence P. Wennogle | M | 74 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 11 years |
| Kimberly E. Vanover | M | 58 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 7 years |
| Rory Riggs | M | 71 |
ITI, Inc. (New York)
| 10 years |
| Joel Marcus | M | 76 |
ITI, Inc. (New York)
| 18 years |
| Robert van Nostrand | M | 67 |
ITI, Inc. (New York)
| 10 years |
| Michael Halstead | M | 51 |
ITI, Inc. (New York)
| 10 years |
| Peter N. Herbert | M | - |
Yale University
| 33 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aaron Kaslow | M | 59 |
Yale University
| 7 years |
| Shakil Waiz Ahmed | M | - |
Yale University
| 6 years |
| Grady S. Vanderhoofven | M | - |
Yale University
| 4 years |
| Jae-Chun Kim | M | 59 |
Yale University
| 2 years |
| Ranjan Goswami | M | - |
Yale University
| 14 years |
| George John Melas-Kyriazi | M | - |
Yale University
| 4 years |
| Patrick Ennis | M | 61 |
Yale University
| 6 years |
| Joseph Patt | M | - |
Yale University
| 4 years |
| Richard Alan Lerner | M | 85 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY. | 11 years |
| Simon Duxbury | M | - |
Yale University
| 4 years |
| Urs F. Greber | M | - |
Yale University
| - |
| Stephen Pike | M | - |
Yale University
| 4 years |
| Matthew Barney | M | 57 |
Yale University
| 4 years |
| Andrew Singer | M | 53 |
Yale University
| 4 years |
| Dennis Charney | M | 72 |
Yale University
| 10 years |
| Gang-Shik Choi | M | 64 |
Yale University
| 3 years |
| Fan Cheong Chan | M | 72 |
Yale University
| 18 years |
| Jack Taylor Thompson | M | 52 |
Yale University
| 4 years |
| Andrew Evan Wolff | M | 55 |
Yale University
| 4 years |
| David Owen Crall | M | - |
Yale University
| 4 years |
| Maxine Williams | F | 53 |
Yale University
| 4 years |
| Petru Ion Vãduva | M | 64 |
Yale University
| 2 years |
| Robert Harding | M | - |
Yale University
| 4 years |
| Bryan Ross Lawrence | M | - |
Yale University
| 4 years |
| Andrew E. Wolff | M | 55 |
Yale University
| 4 years |
| Neil M. Hohmann | M | - |
Yale University
| 4 years |
| Nick Grouf | M | - |
Yale University
| 4 years |
| Ashwini Kumar Nangia | M | - |
Yale University
| 5 years |
| Hai Tao Li | M | 54 |
Yale University
| 1 years |
| Tom Newell | M | - |
Yale University
| 4 years |
| Sean Murphy | M | - |
Yale University
| 5 years |
| Jia Hong Gao | M | 63 |
Yale University
| 6 years |
| Kristin Kyoko Altman | F | 56 |
Yale University
| 4 years |
| Nell Breyer | F | - |
Yale University
| 4 years |
| Mark Laudy | M | - |
Yale University
| 4 years |
| Matt Mochary | M | - |
Yale University
| 4 years |
| Ke Wei Xie | M | 63 |
Yale University
| 3 years |
| Thomas Simonds | M | - |
Yale University
| 4 years |
| Ted Hillenmeyer | M | - |
Yale University
| 4 years |
| Craig Kennedy | M | - |
Yale University
| 4 years |
| Colin Savage | M | - |
Yale University
| 4 years |
| Lin Zhou | M | 64 |
Yale University
| 7 years |
| Buddy Gumina | M | - |
Yale University
| 4 years |
| David Schwimmer | M | 55 |
Yale University
| 4 years |
| Veronica Wu | M | 53 |
Yale University
| 4 years |
| Kevin DeLeon | M | 56 |
Yale University
| 4 years |
| Margaret McLoughlin | M | 60 |
Yale University
| - |
| Shelia Violette | M | - |
Yale University
| 6 years |
| Sandor Barna | M | 55 |
Yale University
| 4 years |
| Ryan A. Rauch | M | - |
Yale University
| 4 years |
| Kenneth Lewis Tananbaum | M | - |
Yale University
| 4 years |
| Charles C. Hale | M | 52 |
Yale University
| 4 years |
| Umut Ergun | M | - |
Yale University
| 4 years |
| Eric W. Kaup | M | 54 |
Yale University
| 4 years |
| Mitchell S. Presser | M | 59 |
Yale University
| 3 years |
| Nicholas G. Demmo | M | - |
Yale University
| 4 years |
| Steven D. Lofchie | M | - |
Yale University
| 3 years |
| Jo Tango | M | - |
Yale University
| 4 years |
| Micah Siegel | M | - |
Yale University
| 4 years |
| Peter Lyons Early | M | - |
Yale University
| 4 years |
| David Sze | M | 58 |
Yale University
| 4 years |
| Jack E. Plym | M | - |
Yale University
| 4 years |
| Tom Clayton | M | - |
Yale University
| 4 years |
| Martin Hale | M | 52 |
Yale University
| 4 years |
| Andy Toburen | M | 52 |
Yale University
| 4 years |
| Robert C. Bruce | M | 62 |
Yale University
| 2 years |
| Montgomery Frank Simus | M | 56 |
Yale University
| 4 years |
| Stefan Kaluzny | M | 57 |
Yale University
| 4 years |
| George Chauncey | M | - |
Yale University
| 3 years |
| Chris Dowd | M | - |
Yale University
| 4 years |
| David Ryan | M | 54 |
Yale University
| 4 years |
| Rob Small | M | 57 |
Yale University
| 4 years |
| Ingrid Kiefer | F | - |
Yale University
| 5 years |
| John V. Calce | M | - |
Yale University
| 4 years |
| Anthony J. Limberis | M | - |
Yale University
| 4 years |
| Francis W. Kelly | M | 75 |
Yale University
| 4 years |
| Daniel Schmedlen | M | - |
Yale University
| 4 years |
| Michael Carrier | M | - |
Yale University
| 4 years |
| David Myles | M | 62 |
Yale University
| 3 years |
| Peter Beinart | M | - |
Yale University
| 4 years |
| Pawel Chudzicki | M | - |
Yale University
| 4 years |
| Vesselin Danev | M | - |
Yale University
| 1 years |
| Philip J. Koh | M | - |
Yale University
| 4 years |
| Chris DeVore | M | - |
Yale University
| 4 years |
| David Ira Schamis | M | 50 |
Yale University
| 4 years |
| Paul Lipari | M | 55 |
Yale University
| 4 years |
| Ajit Nedungadi | M | 54 |
Yale University
| 4 years |
| David S. Blatt | M | - |
Yale University
| 3 years |
| May Han | M | - |
Yale University
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Allen A. Fienberg
- Personal Network
